Publications by authors named "T Moriwaki"
The development of antibody drugs through animal immunization typically requires the humanization of host antibodies to address concerns about immunogenicity in humans. However, employing an animal model capable of producing human antibodies presents the opportunity to develop antibody drugs without the need for humanization. Despite the ratio of human immunoglobulin (Ig) κ to Igλ usage being approximately 60%:40%, the majority of approved antibody therapeutics are kappa antibodies, and the development of lambda antibodies as therapeutic agents has lagged behind.
View Article and Find Full Text PDFArticle Synopsis
- - The study investigates the metabolic profiles of human induced pluripotent stem cell-derived cardiomyocytes (hiPSC-CMs) after their transplantation, showing that these grafts mature from relying on glycolysis to utilizing fatty acid oxidation over time.
- - Researchers also explored teratomas, which can arise from non-cardiomyocyte cells within transplanted hiPSCs, finding elevated amino acid transporters and accumulation of specific amino acids like methionine in these tumors.
- - The presence of subcutaneous teratomas from undifferentiated hiPSCs can be detected through positron emission tomography using a specific tracer, highlighting its relevance in assessing the safety of cardiac regenerative therapies.
Fibroblast growth factor receptors (FGFRs) are a highly conserved family of transmembrane receptor tyrosine kinases with multiple roles in the regulation of key cellular processes. Specific FGFR mutations have been observed in several types of cancers, including gastric carcinoma and cholangiocarcinoma. Dose escalation data of 24 Japanese patients with solid tumors treated with Tasurgratinib (previously known as E7090), a potent, selective FGFR1-3 inhibitor, was reported in a phase I, first-in-human, single-center study.
View Article and Find Full Text PDFWe herein report a patient with Lynch-like syndrome in whom a brain tumor (glioblastoma) developed after repeated resection of colorectal cancer. The patient had a significant family history of cancer. Immunohistochemical expression of mismatch repair proteins was decreased in both brain and colon tumors, but no pathogenic variant of the related genes was detected.
View Article and Find Full Text PDFArticle Synopsis
- FOLFOXIRI plus bevacizumab is a first-line chemotherapy for metastatic colorectal cancer, but is rarely used due to severe side effects, with limited real-world efficacy and safety data available.
- A study analyzed clinical data from 104 patients, finding that 63% required dose reductions and that treatment discontinuation was primarily due to toxicities, with 45% completing the planned therapy cycles.
- Results showed promising outcomes with a median progression-free survival of 12.8 months and overall survival of 27.9 months, along with a high disease control rate of 98.9%, and no treatment-related deaths reported.